+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Identification of novel selective P2Y 6 receptor antagonists by high-throughput screening assay



Identification of novel selective P2Y 6 receptor antagonists by high-throughput screening assay



Life Sciences 180: 137-142



The P2Y6 nucleotide receptor is widely involved in inflammatory responses, and is a promising molecular target for the treatment of inflammatory diseases. Although several P2Y6 receptor antagonists have been developed and evaluated thus far, none has successfully been developed into a therapeutic drug. In this study, we explored new promising compounds that inhibit the human P2Y6 receptor. High-throughput screening (HTS) was used to study the effects of various compounds on human P2Y6 receptors expressed in 1321N1 human astrocytoma cells by monitoring intracellular Ca2+ concentration ([Ca2+]i) levels using an FDSS7000 real-time fluorescence detector. IL-8 concentration was measured by enzyme-linked immunosorbent assay. Among structurally diverse chemical libraries totalling 141,700 compounds, 43 compounds with an inhibitory activity against the P2Y6 receptor were identified. Further studies using a dose-response assay, receptor selectivity assay, and chemokine measurement assay revealed the selective P2Y6 receptor inhibitor TIM-38, which inhibited UDP-induced [Ca2+]i elevation in a dose-dependent manner. TIM-38 had an IC50 value of 4.3μM and inhibited P2Y6 without affecting the response induced by four other human P2Y or muscarinic receptors. In addition, TIM-38 inhibited UDP-induced interleukin-8 release in a dose-dependent manner without affecting releases caused by other stimulus such as interleukin-1β or tumour necrosis factor-α. Analyses of TIM-38 derivatives revealed that the nitro moiety is vital to P2Y6 receptor inhibition. TIM-38 acts as a novel structural antagonist of P2Y6 receptor and may be a good lead compound for developing a P2Y6 receptor-targeted anti-inflammatory drug.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059824880

Download citation: RISBibTeXText

PMID: 28527783

DOI: 10.1016/j.lfs.2017.05.017


Related references

Discovery of antagonists for human scavenger receptor CD36 via an ELISA-like high-throughput screening assay. Journal of Biomolecular Screening 15(3): 239-250, 2010

Identification of two antagonists of the scavenger receptor CD36 using a high-throughput screening model. Analytical Biochemistry 400(2): 207-212, 2010

Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening. Molecular Pharmacology 77(1): 46-57, 2010

Ultra-high-throughput screening for antagonists of a Gi-coupled receptor in a 2.2-microl 3,456-well plate format cyclicAMP assay. Assay and Drug Development Technologies 5(1): 117-125, 2007

A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists. Assay and Drug Development Technologies 3(4): 393-400, 2005

Identification of metabotropic glutamate receptor antagonists using an automated high-throughput screening system. Analytical Biochemistry 313(2): 246-254, February 15, 2003

Development of a time-resolved fluorometric assay for the high throughput screening of melanin concentrating hormone receptor antagonists. Journal of Pharmacological and Toxicological Methods 53(3): 242-247, 2005

A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: High-throughput screening and identification of selective enzyme inhibitors. Analytical Biochemistry 268(2): 318-329, March 15, 1999

Identification of novel human high-density lipoprotein receptor Up-regulators using a cell-based high-throughput screening assay. Journal of Biomolecular Screening 12(2): 211-219, 2007

Development of the high throughput screening assay for identification of agonists of an orphan nuclear receptor. Assay and Drug Development Technologies 4(3): 253-262, 2006

High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. Journal of Biomolecular Screening 10(5): 463-475, 2005

A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor. Assay and Drug Development Technologies 12(4): 238-246, 2015

Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists. Journal of Pharmacology and Experimental Therapeutics 333(3): 650-662, 2010

High-throughput screening using beta-lactamase reporter-gene technology for identification of low-molecular-weight antagonists of the human gonadotropin releasing hormone receptor. Assay and Drug Development Technologies 3(2): 143-154, 2005

Progesterone receptor chaperone complex-based high-throughput screening assay: identification of capsaicin as an inhibitor of the Hsp90 machine. Journal of Biomolecular Screening 20(2): 223-229, 2015